NeoDynamics introduces NeoNavia®, a micropulse biopsy system, to a wider audience in the UK
Press release
November 6, 2018
NeoDynamics introduces NeoNavia®, a micropulse biopsy system, to a wider audience in the UK at the British Society of Breast Radiology Annual Scientific Meeting 2018 in Newcastle
As the commercial launch of NeoNavia, rapidly approaches in 2019, NeoDynamics will showcase its new biopsy system, with micropulse technology, for the British Society of Breast Radiology (BSBR) during their annual meeting 4-6th November in Newcastle.
NeoDynamics now introduces the novel patented micropulse driven biopsy technology in the UK. Simultaneously the CE marked study version of NeoNavia is available for equipment testing in selected breast cancer clinics until the commercial enhanced NeoNavia is expected to launch in the UK late 2019.
“There is no doubt that there is a need for novel alternatives in breast cancer biopsy systems. Technologies that can improve patient comfort as well as operator experience during biopsy are especially welcome” says Dr Steve Allen at the Royal Marsden NHS Foundation Trust in London. “Our tests of NeoNavia indicate that the micropulse technology does seem to increase the technical precision and sense of control during the biopsy” Dr Allen concludes.
In cooperation and partnership with breast radiology societies and radiology clinics in the United Kingdom, NeoDynamics intends to arrange introduction events for NeoNavia micropulse biopsy system during 2019. With NeoNavia NeoDynamics has an ambition to further advance the development of breast biopsy in breast cancer diagnosis.
The aim is to get five or more clinics in the United Kingdom to test and evaluate the CE-marked study version of NeoNavia. When the commercial version arrives in late 2019 radiologists will have had the opportunity to get a feel for the micropulse technology and consider it as an option for the future development of breast biopsy at their clinic.
“We want to raise awareness of our new micropulse driven biopsy system NeoNavia and spark an interest among physicians in the UK who are involved in development of breast cancer diagnostics” says Anna Eriksrud, CEO of NeoDynamics about their presence at the BSBR 2018 in Newcastle.
For further information about NeoDynamics, please contact:
Anna Eriksrud, CEO NeoDynamics AB (publ)
Telephone: +46 8 522 79 667
E-mail: anna.eriksrud@neodynamics.se
About NeoDynamics
Every year, approximately 2.1 million women worldwide are diagnosed with breast cancer, increasing by five percent per year. NeoDynamics has developed the NeoNavia® biopsy system which facilitates and improves tissue sampling (biopsies) in breast cancer patients, with a new patented micropulse technology. This method gives precision and control. In close collaboration with leading clinicians, we have gained experience of having used the technology in more than 300 procedures at around 15 university hospitals across Europe. NeoDynamics is currently completing development of the commercial version of NeoNavia. Among several design and usability features it integrates micropulse technology with multiple needle options for maximum versatility. NeoNavia is expected to be launched towards the end of 2019 in a breast biopsy market worth approximately USD 500 million per year. The technology is likewise suited for cancer diagnostics in other organs such as prostate, lung, kidney and liver.
Micropulse technology
The micropulse technology is based on a pneumatic insertion mechanism that enables precise and user controlled needle insertion regardless of tissue characteristics. Stepwise needle insertion without noticeable deformation or displacement of surrounding tissue is achieved and visualized under ultrasound.
NeoNavia®
NeoNavia biopsy system is composed of a base unit and a biopsy device, and is operated together with ultrasound imaging guidance. The base unit supplies the biopsy device with power and controls the operation during the biopsy procedure. The current sampling needle is designed to facilitate maximum sampling yield with minimal trauma. This makes the NeoNavia system particularly well suited for ensuring safe and precise sampling of technically challenging lesions. These might be lesions difficult to reach or target, lesions near delicate anatomical structures, and lesions that are easily displaced by the biopsy needle tip, resulting in the collection of non-representative samples.
Currently NeoNavia exists in a CE-marked study version and since late 2016 it has been tested by leading specialists at some 15 cancer centers in Europe, evaluating both the micropulse technology and FlexiPulse needle design in order to demonstrate its strengths. More than 300 patients have undergone breast and axillary lymph node biopsies with this new micropulse technology and a clinical study is currently ongoing in Germany to further establish the technology. The study version has been vital for the development of the enhanced NeoNavia biopsy system planned for commercial launch late 2019.